Abstract
Effective prophylaxis and treatment of corneal graft rejection are essential to improve outcomes in corneal transplantation. To date, there has been no standardized protocol published that outlines the optimal prophylactic and therapeutic approaches and, furthermore, the published controlled trials on this subject are limited. Likewise, no study has addressed how the level of antigen exposure varies between different types of keratoplasties. The aim of this paper is to provide a simple evidence-based protocol for the prevention and treatment of corneal graft rejection.
摘要
对于角膜移植术后的排斥反应进行有效的预防和治疗对与改善角膜移植术的预后至关重要。到目前为止, 还未有针对角膜移植排斥的最佳预防与治疗方法的标准方案, 另外, 已发表的对照试验例数有限。更没有研究证实不同类型的角膜移植术后抗原暴露程度如何变化。本文旨在提供一个简单的、具有循证依据的针对角膜移植术后角膜移植排斥反应的临床方案。
预防和治疗角膜移植排斥的文献回顾与建议方案
摘要: 对于角膜移植术后的排斥反应进行有效的预防和治疗对与改善角膜移植术的预后至关重要。到目前为止,还未有针对角膜移植排斥的最佳预防与治疗方法的标准方案,另外,已发表的对照试验例数有限。更没有研究证实不同类型的角膜移植术后抗原暴露程度如何变化。本文旨在提供一个简单的、具有循证依据的针对角膜移植术后角膜移植排斥反应的临床方案。
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Patel NP, Kim T, Rapuano CJ, Cohen EJ, Laibson PR. Indications for and outcomes of repeat penetrating keratoplasty, 1989–1995. Ophthalmology. 2000;107:719–24.
Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25:286–90.
Pineda R. Corneal transplantation in the developing world: lessons learned and meeting the challenge. Cornea. 2015;34:35–40.
Kharod-Dholakia B, Randleman JB, Bromley JG, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns of the Cornea Society (2011). Cornea. 2015;34:609–14.
Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Exp Ophthalmol. 2008;36:415–21.
Sinha R, Jhanji V, Verma K, Sharma N, Biswas NR, Vajpayee RB. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1167–72.
Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea. 2008;27:488–93.
Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381–90.
Anshu A, Price MO, Price FW. Risk of corneal transplant rejection significantly reduced with Descemet’s membrane endothelial keratoplasty. Ophthalmol. 2012;119:536–40.
Olson EA, Tu EY, Basti S. Stromal rejection following deep anterior lamellar keratoplasty: implications for postoperative care. Cornea. 2012;31:969–73.
Belin MW, Villavicencio OF, Ambrosio RJR. Tomographic parameters for the detection of keratoconus: suggestions for screening and treatment parameters. Eye Contact lens. 2014;40:326–30.
Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005;24:292–6.
Price FW Jr, Price DA, Ngakeng V, Price MO. Survey of steroid usage patterns during and after low-risk penetrating keratoplasty. Cornea. 2009;28:865–70.
Diederich S, Scholz T, Eigendorff E, Bumke-Vogt Ch, Quinkler M, Exner P, et al. Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res. 2004;36:423–9.
Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708–13.
Shimazaki J, Iseda A, Satake Y, Shimazaki-Den S. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial. Ophthalmology. 2012;119:668–73.
Kupferman A, Berrospi AR, Leibowitz HM. Fluorometholone acetate. A new ophthalmic derivative of fluorometholone. Arch Ophthalmol. 1982;100:640–1.
Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharm. 2018;19:337–53.
Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmol. 2002;109:1887–91.
McGhee CN, Noble MJ, Watson DG, Dutton GN, Fern AI, Healey TM, et al. Penetration of topically applied prednisolone sodium phosphate into human aqueous humour. Eye. 1989;3:463–7.
Kusne Y, Kang P, Fintelmann RE. A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%. Clin Ophthalmol. 2016;10:2329–36.
Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmol. 1991;98:329–33.
Vinciguerra P, Albé E, Vinciguerra R, Romano MR, Trazza S, Mastropasqua L, et al. Long-term resolution of immunological graft rejection after a dexamethasone intravitreal implant. Cornea. 2015;34:471–4.
Sugar A, Bokosky JE, Meyer RF. A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. Cornea. 1984;3:268–71.
Rinne JR, Stulting RD. Current practices in the prevention and treatment of corneal graft rejection. Cornea. 1992;11:326–8.
Unal M, Yücel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92:1411–4.
Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785–90.
Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology. 1989;96:1144–50.
Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol. 2011;152:33–39.
Bock F, Matthaei M, Reinhard T, Böhringer D, Christoph J, Ganslandt T, et al. High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty. Ophthalmology. 2014;121:1677–82.
Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci. 1997;38:901–9.
Magalhaes OA, Marinho DR, Kwitko S. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol. 2013;97:1395–8.
Sloper CML, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmol. 2001;108:1838–44.
Vassileva PI, Hergeldzhieva TG. Avastin use in high-risk corneal transplantation. Graefe’s Arch Clin Exp Ophthalmol. 2009;247:1701–6.
Dekaris I, Gabrić N, Drača N, Pauk-Gulić M, Miličić N. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefe’s Arch Clin Exp Ophthalmol. 2015;253:287–94.
Bhatti N, Qidwai U, Kazi A. Efficacy of sub-conjunctival and topical bevacizumab in high-risk corneal transplant survival. J Pak Med Assoc. 2013;63:1256–9.
Belghmaidi S, Hajji, Ennassiri W, Benhaddou R, Baha Ali T, Moutaouakil A. Managemet of corneal neovascularization prior to corneal transplantation: Reports of 112 cases. J Fr Ophtalmol. 2016;39:515–20.
Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe. 2002;99:38–45.
Birnbaum F, Böhringer D, Sokolovska Y, Sundmacher R, Reinhard T. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplant. 2005;79:964–8.
Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol. 1999;83:1268–71.
Stanojlovic S, Schlickeiser S, Appelt C, Vogt K, Schmitt-Knosalla I, Haase S, et al. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol. 2010;248:1447–56.
Chatel MA, Larkin DFP. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol. 2010;150:179–84.
Nguyen P, Barte F, Shinada S, Yiu SC. Management of corneal graft rejection a case series report and review of the literature. J Clin Exp Ophthalmol. 2010;1:100–3.
Friedman J, Marcovich AL, Kleinmann G, Schattner A. Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea. 2014;33:1066–70.
Khan IJ, Barry RJ, Amissah-Arthur KN, Carruthers D, Elamanchi SR, Situnayake D, et al. Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol. 2013;97:1118–22.
Park CY, Lee JK, Gore PK, Lim CY, Chuck RS. Keratoplasty in the United States. Ophthalmology. 2015;122:2432–42.
Yildiz E, Toklu M, Turan Vural E. Vision-related quality of life before and after deep anterior lamellar keratoplasty. Eye Contact Lens. 2018;44:144–8.
Henein C, Nanavaty MA. Systematic review comparing penetrating keratoplasty and deep anterior lamellar keratoplasty for management of keratoconus. Cont Lens Anterior Eye. 2017;40:3–14.
Watson SL, Tuft SJ, Dart JKG. Patterns of rejection after deep lamellar keratoplasty. Ophthalmology. 2006;113:556–60.
Gonzalez A, Price MO, Feng MT, Lee C, Arbelaez JG, Price FW Jr. Immunologic rejection episodes after deep anterior lamellar keratoplasty: incidence and risk factors. Cornea. 2017;36:1076–82.
Roberts HW, Maycock NJ, OʼBrart DP. Late stromal rejection in deep anterior lamellar keratoplasty: a case series. Cornea. 2016;35:1179–81.
Borderie VM, Guilbert E, Touzeau O, Laroche L. Graft rejection and graft failure after anterior lamellar versus penetrating keratoplasty. Am J Ophthalmol. 2011;151:1024–9.
Magalhaes OA, Marafon SB, Ferreira RC. Gender differences in keratoconus keratoplasty: a 25-year study in Southern Brazil and global perspective. Int Ophthalmol. 2018;38:1627–33.
Reddy JC, Murthy SI, Vaddavalli PK, Garg P, Ramappa M, Chaurasia S, et al. Clinical outcomes and risk factors for graft failure after deep anterior lamellar keratoplasty and penetrating keratoplasty for macular corneal dystrophy. Cornea. 2015;34:171–6.
Kim BZ, Meyer JJ, Brookes NH, Moffatt SL, Twohill HC, Pendergrast DG, et al. New Zealand trends in corneal transplantation over the 25 years 1991–2015. Br J Ophthalmol. 2017;10:834–8.
Chan SWS, Yucel Y, Gupta N. New trends in corneal transplants at the University of Toronto. Can J Ophthalmol. 2018;6:580–7.
Ang M, Soh Y, Htoon HM, Mehta JS, Tan D. Five-year graft survival comparing descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. Ophthalmol. 2016;123:1646–52.
Li JY, Terry MA, Goshe J, et al. Graft rejection after Descemet’s stripping automated endothelial keratoplasty: graft survival and endothelial cell loss. Ophthalmology. 2012;119:90–94.
Jordan CS, Price MO, Trespalacios R, et al. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part one: clinical signs and symptoms. Br J Ophthalmol. 2009;93:387–90.
Sepsakos L, Shah K, Lindquist TP, et al. Rate of rejection after descemet stripping automated endothelial keratoplasty in fuchs dystrophy: three-year follow-up. Cornea. 2016;35:1537–41.
Price MO, Price FW Jr, Kruse FE, et al. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after Descemet membrane endothelial keratoplasty. Cornea. 2014;33:880–6.
Price MO, Feng MT, Scanameo A, et al. Loteprednol etabonate 0.5% Gel vs. prednisolone acetate 1% solution after Descemet membrane endothelial keratoplasty: prospective randomized trial. Cornea. 2015;34:853–8.
Price MO, Scanameo A, Feng MT, Price FW Jr. Descemet’s membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. Ophthalmology. 2016;123:1232–6.
Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599–604.
Hill JC, Maske R, Watson PG. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report. Eye. 1991;5:420–4.
Hill JC. Immunosuppression in corneal transplantation. Eye. 1995;9:247–53.
Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol. 1995;119:189–94.
Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348–52.
Athanasiadis I, de Wit D, Tsatsos M, Patel AK, Sharma A. Subconjunctival injection of triamcinolone acetonide in the management of corneal graft rejection and new vessels. J Clin Pharm. 2012;52:607–12.
Hashemian MN, Latifi G, Ghaffari R, Ghassemi H, Zarei-Ghanavati M, Mohammadi SF, et al. Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial. Cornea. 2018;37:307–12.
Ghaffari R, Ghassemi H, Zarei-Ghanavati M, Latifi G, Dehghani S, Haq Z, et al. Tacrolimus Eye Drops as Adjunct Therapy in Severe Corneal Endothelial Rejection Refractory to Corticosteroids. Cornea. 2017;10:1195–9.
Maris PJ Jr, Correnti AJ, Donnenfeld ED. Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty. Cornea. 2008;27:847–50.
Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: a pilot study. Transpl Int. 2002;15:81–8.
Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol. 2003;241:1051–4.
Barney NP, Foster CS. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 1994;13:232–6.
Jansen AF, Rijneveld WJ, Remeijer L, Jansen AF, Rijneveld WJ, Remeijer L, et al. Five-year follow-up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. Cornea. 2009;28:843–5.
Brik D, Dunkel E, Pavan-Langston D. Herpetic keratitis: persistence of viral particles despite topical and systemic antiviral therapy. Report of two cases and review of the literature. Arch Ophthalmol. 1993;111:522–7.
Banerjee S, Dick AD. Recent developments in the pharmacological treatment and prevention of corneal graft rejection. Expert Opin Invest Drugs. 2003;12:29–37.
Segoloni GP, Quaglia M. New immunosuppressive drugs for prevention and treatment of rejection in renal transplant. J Nephrol. 2006;19:578–86.
Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol. 2008;28:223–32.
Baradaran-Rafii A, Eslani M, Djalillian AR. Complications of keratolimbal allograft surgery. Cornea. 2013;32:561–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Azevedo Magalhaes, O., Shalaby Bardan, A., Zarei-Ghanavati, M. et al. Literature review and suggested protocol for prevention and treatment of corneal graft rejection. Eye 34, 442–450 (2020). https://doi.org/10.1038/s41433-019-0517-9
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-019-0517-9
This article is cited by
-
Management of corneal allograft rejection in post-penetrating keratoplasty patients: a retrospective analysis
Cell and Tissue Banking (2026)
-
Tacrolimus eye drops treatment for recurrent exposure of the Ahmed glaucoma valve tube
European Journal of Medical Research (2025)
-
The role of graft cross-linking during keratoplasty in patients with corneal melting
Scientific Reports (2024)
-
Immunosuppressive Therapy for High-Risk Corneal Transplant
Current Ophthalmology Reports (2022)
